Latest & greatest articles for hydrocortisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydrocortisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydrocortisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydrocortisone

1. Comparison Between Continuous and Intermittent Administration of Hydrocortisone During Septic Shock: A Randomized Controlled Clinical Trial

Comparison Between Continuous and Intermittent Administration of Hydrocortisone During Septic Shock: A Randomized Controlled Clinical Trial The best modality of administration of hydrocortisone during septic shock has been poorly evaluated and the guidelines remain unclear in this respect. This study aimed to compare bolus of hydrocortisone to a continuous infusion during septic shock.Randomized controlled, open-label trial.Medical ICU of a university hospital.Adult patients with septic shock (...) requiring more than 2 mg/h (approximately 33.3 μg/mn) of norepinephrine after adequate fluid administration were eligible.Patients already receiving corticosteroids or who have a contraindication to corticosteroids, patients who died within 24 h and those with a decision of not to resuscitate were excluded.Patients were randomized either to receive hydrocortisone 200 mg/d by continuous infusion or by boluses of 50 mg every 6 h throughout the prescription of vasopressors with a maximum of 7 days.Twenty

2019 EvidenceUpdates

2. A Randomized Controlled Study of Low-Dose Hydrocortisone Versus Placebo in Dopamine-Treated Hypotensive Neonates Undergoing Hypothermia Treatment for Hypoxic-Ischemic Encephalopathy

A Randomized Controlled Study of Low-Dose Hydrocortisone Versus Placebo in Dopamine-Treated Hypotensive Neonates Undergoing Hypothermia Treatment for Hypoxic-Ischemic Encephalopathy To investigate whether hydrocortisone supplementation increases blood pressure and decreases inotrope requirements compared with placebo in cooled, asphyxiated neonates with volume-resistant hypotension.A double-blind, randomized, placebo-controlled clinical trial was conducted in a Level III neonatal intensive care (...) unit in 2016-2017. Thirty-five asphyxiated neonates with volume-resistant hypotension (defined as a mean arterial pressure [MAP] < gestational age in weeks) were randomly assigned to receive 0.5 mg/kg/6 hours of hydrocortisone or placebo in addition to standard dopamine treatment during hypothermia.More patients reached the target of at least 5-mm Hg increment of MAP in 2 hours after randomization in the hydrocortisone group, compared with the placebo group (94% vs 58%, P = .02, intention-to-treat

2019 EvidenceUpdates

3. The Association of Hydrocortisone Dosage on Mortality in Infants Born Extremely Premature

The Association of Hydrocortisone Dosage on Mortality in Infants Born Extremely Premature To characterize common dosing strategies and to investigate the association between hydrocortisone dosage and in-hospital mortality in infants born extremely premature.We performed a retrospective review of a cohort of infants born ≤30 weeks' gestational age from 2010 to 2016 from the Pediatrix Clinical Data Warehouse who received hydrocortisone in the first 14 postnatal days. Infants were divided (...) by initial hydrocortisone dosage (high: >2 mg/kg/d vs low: ≤2 mg/kg/d). Baseline characteristics and medication coexposures were compared and mortality was evaluated in a multivariable analysis.A total of 1427 infants were included, 733 with high dosage (51%) and 694 with low dosage (49%). The groups were similar with regard to baseline characteristics. Infants in the high-dosage group had significantly more exposure to any vasopressors (89% vs 84%, P < .001) and greater mortality (50% vs 23%, P < .001

2019 EvidenceUpdates

4. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial. (PubMed)

Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial. Dexamethasone initiated after the first week of life reduces the rate of death or bronchopulmonary dysplasia (BPD) but may cause long-term adverse effects in very preterm infants. Hydrocortisone is increasingly used as an alternative, but evidence supporting its efficacy and safety is lacking.To (...) assess the effect of hydrocortisone initiated between 7 and 14 days after birth on death or BPD in very preterm infants.Double-blind, placebo-controlled randomized trial conducted in 19 neonatal intensive care units in the Netherlands and Belgium from November 15, 2011, to December 23, 2016, among preterm infants with a gestational age of less than 30 weeks and/or birth weight of less than 1250 g who were ventilator dependent between 7 and 14 days of life, with follow-up to hospital discharge ending

Full Text available with Trip Pro

2019 JAMA Controlled trial quality: predicted high

5. Prognostic model based on baseline predictors to estimate risk of bronchopulmonary dysplasia given hydrocortisone prophylaxis

Prognostic model based on baseline predictors to estimate risk of bronchopulmonary dysplasia given hydrocortisone prophylaxis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

6. Effect of hydrocortisone for adults patients with septic shock unresponsive to initial fluid administration and vasoactive agents: a systematic review

Effect of hydrocortisone for adults patients with septic shock unresponsive to initial fluid administration and vasoactive agents: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

7. Fludrocortisone with hydrocortisone for adult patients with septic shock

Fludrocortisone with hydrocortisone for adult patients with septic shock Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

8. Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks

Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks - GOV.UK GOV.UK uses cookies to make the site simpler. Search Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks Risk of insufficient cortisol (...) absorption and life-threatening adrenal crisis if muco-adhesive buccal tablets are used as adrenal replacement therapy. Published 18 December 2018 From: Therapeutic area: , Contents Advice for healthcare professionals hydrocortisone muco-adhesive buccal tablets are indicated only for local use in the mouth for aphthous ulceration and should not be used for treating adrenal insufficiency substitution of licensed oral formulations of hydrocortisone with muco-adhesive buccal tablets can result

2019 MHRA Drug Safety Update

9. Effect of Prophylaxis for Early Adrenal Insufficiency Using Low-Dose Hydrocortisone in Very Preterm Infants: An Individual Patient Data Meta-Analysis

Effect of Prophylaxis for Early Adrenal Insufficiency Using Low-Dose Hydrocortisone in Very Preterm Infants: An Individual Patient Data Meta-Analysis To assess the effect of prophylaxis for early adrenal insufficiency using low-dose hydrocortisone on survival without bronchopulmonary dysplasia (BPD) in very preterm infants using an individual patient data meta-analysis.All existing randomized controlled trials testing the efficacy of the prophylaxis of early adrenal insufficiency using low-dose (...) hydrocortisone on survival without BPD were considered for inclusion when data were available. The primary outcome was the binary variable survival without BPD at 36 weeks of postmenstrual age.Among 5 eligible studies, 4 randomized controlled trials had individual patient data available (96% of participants identified; n = 982). Early low-dose hydrocortisone treatment for 10-15 days was associated with a significant increase in survival without BPD (OR, 1.45; 95% CI, 1.11-1.90; P = .007; I2 = 0%), as well

Full Text available with Trip Pro

2019 EvidenceUpdates

10. Hydrocortisone Granules Are Bioequivalent When Sprinkled Onto Food or Given Directly on the Tongue. (PubMed)

Hydrocortisone Granules Are Bioequivalent When Sprinkled Onto Food or Given Directly on the Tongue. Immediate-release hydrocortisone granules in capsules for opening in pediatric-appropriate doses have recently been licensed for children with adrenal insufficiency. This study evaluated the bioavailability of hydrocortisone granules administered as sprinkles onto soft food and yogurt compared with direct administration to the back of the tongue.Randomized, 3-period crossover study in 18 (...) dexamethasone-suppressed healthy men. In each period, the fasted participants received 5 mg hydrocortisone granules either directly to the back of the tongue or sprinkled onto soft food (applesauce), or yogurt, followed by 240 mL of water. Serum cortisol was measured by liquid chromatography tandem mass spectometry.The cortisol geometric mean maximum concentration (Cmax) and area under the curve (AUC) for direct administration, sprinkles onto yogurt, and sprinkles onto soft food were: Cmax 428, 426, 427

Full Text available with Trip Pro

2019 Journal of the Endocrine Society Controlled trial quality: uncertain

11. Hydrocortisone (Alkindi) - replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to <18 years old)

Hydrocortisone (Alkindi) - replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to <18 years old) Published 08 October 2018 1 hydrocortisone 0.5mg, 1mg, 2mg and 5mg granules in capsules for opening (Alkindi ® ) SMC2088 Diurnal Limited 7 September 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarized as follows: ADVICE: following a full submission hydrocortisone (Alkindi ® ) is accepted for restricted use within NHSScotland. Indication under review: replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to <18 years old). SMC restriction: for the first-line treatment of infants and young children with adrenal insufficiency aged from birth to less than six years of age for whom hydrocortisone must otherwise be individually prepared by manipulation

2018 Scottish Medicines Consortium

12. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study

Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2018 PedsCCM Evidence-Based Journal Club

13. Hydrocortisone

Hydrocortisone Top results for hydrocortisone - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hydrocortisone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

14. Hydrocortisone (Alkindi) - Adrenal Insufficiency

Hydrocortisone (Alkindi) - Adrenal Insufficiency 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 14 December 2017 EMA/4145/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Alkindi International non (...) -proprietary name: hydrocortisone Procedure No. EMEA/H/C/004416/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/4145/2018 Page 2/59 Table of contents 1. Background information on the procedure 7 1.1. Submission of the dossier 7 1.2. Steps taken for the assessment of the product 8 2. Scientific discussion 9 2.1. Introduction 9 2.1.1. Disease or condition 10 2.1.2. Epidemiology 11 2.1.3. Clinical presentation

2018 European Medicines Agency - EPARs

15. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. (PubMed)

Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock.In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design (...) , we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from

Full Text available with Trip Pro

2018 NEJM Controlled trial quality: predicted high

16. Hydrocortisone (adrenal insufficiency) - Benefit assessment according to §35a Social Code Book V

Hydrocortisone (adrenal insufficiency) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Hydrocortison (Nebenniereninsuffizienz bei Kindern) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 10 August 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. IQWiG Reports – Commission No. A18-29 Hydrocortisone (adrenal insufficiency in children) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-29 Version 1.0 Hydrocortisone (adrenal insufficiency in children) 10 August 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Hydrocortisone (adrenal insufficiency in children

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

18. Impact of hydrocortisone in sepsis and septic shock on mortality. A protocol of literature review and meta-analysis

Impact of hydrocortisone in sepsis and septic shock on mortality. A protocol of literature review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

19. Hydrocortisone sodium phosphate (Softacor) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases

Hydrocortisone sodium phosphate (Softacor) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases Hydrocortisone sodium phosphate (Softacor®) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases | Report | National Health Care Institute You are here: Hydrocortisone sodium phosphate (Softacor®) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases Search within English part of National Health (...) Care Institute Search Hydrocortisone sodium phosphate (Softacor®) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases Zorginstituut Nederland has carried out an assessment of the medicinal product hydrocortisone sodium phosphate (Softacor®) can be included in the Medicine Reimbursement System (GVS). The Ministry requested a marginal assessment. Softacor® is an ocular corticosteroid registered for the treatment of mild non-infectious allergic or inflammatory

2018 National Health Care Institute (Zorginstituut Nederland)

20. The effects of low dose hydrocortisone in patients with sepsis or septic shock

The effects of low dose hydrocortisone in patients with sepsis or septic shock Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO